Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Director Purchases $21,708.80 in Stock

Share on StockTwits

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Director Albert Cha purchased 1,280 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was acquired at an average price of $16.96 per share, with a total value of $21,708.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Albert Cha also recently made the following trade(s):

  • On Friday, July 19th, Albert Cha acquired 61,280 shares of Kalvista Pharmaceuticals stock. The shares were purchased at an average cost of $17.79 per share, for a total transaction of $1,090,171.20.

KALV opened at $17.55 on Monday. Kalvista Pharmaceuticals Inc has a 52-week low of $7.95 and a 52-week high of $34.92. The firm has a market capitalization of $305.16 million, a P/E ratio of -12.72 and a beta of 2.12. The firm’s 50-day moving average is $19.70.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Monday, July 15th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.07). Kalvista Pharmaceuticals had a negative net margin of 127.20% and a negative return on equity of 24.57%. The firm had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $3.64 million. On average, sell-side analysts forecast that Kalvista Pharmaceuticals Inc will post -2.52 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on KALV shares. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 9th. TheStreet raised shares of VEON from a “d+” rating to a “c-” rating in a report on Thursday, July 11th. Roth Capital restated a “buy” rating on shares of Kalvista Pharmaceuticals in a research note on Tuesday, May 28th. Zacks Investment Research cut shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research report on Wednesday, July 17th. Finally, ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Kalvista Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $29.40.

Several hedge funds have recently made changes to their positions in KALV. FMR LLC acquired a new position in Kalvista Pharmaceuticals in the 1st quarter valued at $21,036,000. Barclays PLC increased its stake in shares of Kalvista Pharmaceuticals by 88,319.7% in the 4th quarter. Barclays PLC now owns 62,778 shares of the specialty pharmaceutical company’s stock worth $1,240,000 after acquiring an additional 62,707 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Kalvista Pharmaceuticals in the 1st quarter worth $843,000. Laurion Capital Management LP increased its stake in shares of Kalvista Pharmaceuticals by 94.9% in the 1st quarter. Laurion Capital Management LP now owns 58,871 shares of the specialty pharmaceutical company’s stock worth $1,685,000 after acquiring an additional 28,670 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in shares of Kalvista Pharmaceuticals by 133.5% during the 4th quarter. BlackRock Inc. now owns 45,078 shares of the specialty pharmaceutical company’s stock worth $891,000 after purchasing an additional 25,769 shares during the period. 80.64% of the stock is owned by institutional investors and hedge funds.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: What does cost of debt say about a company’s financial health?

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.